Aigen Investment Management LP Purchases 430 Shares of Enovis Co. (NYSE:ENOV)

Aigen Investment Management LP raised its position in shares of Enovis Co. (NYSE:ENOV) by 5.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,859 shares of the company’s stock after acquiring an additional 430 shares during the quarter. Aigen Investment Management LP’s holdings in Enovis were worth $381,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. River Road Asset Management LLC acquired a new stake in Enovis in the third quarter worth $51,341,000. American Century Companies Inc. boosted its position in shares of Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company’s stock worth $68,337,000 after purchasing an additional 665,208 shares in the last quarter. Magnetar Financial LLC grew its stake in shares of Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after buying an additional 442,051 shares during the period. Diamond Hill Capital Management Inc. increased its position in Enovis by 14.5% in the 2nd quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company’s stock valued at $125,929,000 after buying an additional 352,116 shares in the last quarter. Finally, Boston Partners raised its stake in Enovis by 206.5% during the 1st quarter. Boston Partners now owns 295,969 shares of the company’s stock worth $18,455,000 after buying an additional 199,411 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Price Performance

ENOV stock opened at $45.59 on Friday. The firm has a market cap of $2.55 billion, a P/E ratio of -20.81 and a beta of 1.91. The firm’s fifty day moving average is $42.33 and its 200 day moving average is $45.33. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same quarter in the previous year, the company posted $0.56 earnings per share. The business’s revenue was up 21.0% on a year-over-year basis. Research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ENOV. JMP Securities began coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective on the stock. Evercore ISI decreased their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lowered their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.